Erythropoietin Just Before Reperfusion Reduces Both Lethal Arrhythmias and Infarct Size via the Phosphatidylinositol-3 Kinase-Dependent Pathway in Canine Hearts
Authors:
- 1 January 2005
- journal article
- basic pharmacology
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 19 (1) , 33-40
Abstract
Although recent studies suggest that erythropoietin (EPO) may reduce multiple features of the myocardial ischemia/reperfusion injury, the cellular mechanisms and the clinical implications of EPO-induced cardioprotection are still unclear. Thus, in this study, we clarified dose-dependent effects of EPO administered just before reperfusion on infarct size and the incidence of ventricular fibrillation and evaluated the involvement of the phosphatidylinositol-3 (PI3) kinase in the in vivo canine model. The canine left anterior descending coronary artery was occluded for 90 min followed by 6 h of reperfusion. A single intravenous administration of EPO just before reperfusion significantly reduced infarct size (high dose (1,000 IU/kg): 7.7 ± 1.6%, low dose (100 IU/kg): 22.1 ± 2.4%, control: 40.0 ± 3.6%) in a dose-dependent manner. Furthermore, the high, but not low, dose of EPO administered as a single injection significantly reduced the incidence of ventricular fibrillation during reperfusion (high dose: 0%, low dose: 40.0%, control: 50.0%). An intracoronary administration of a PI3 kinase inhibitor, wortmannin, blunted the infarct size-limiting and anti-arrhythmic effects of EPO. Low and high doses of EPO equally induced Akt phosphorylation and decreased the equivalent number of TUNEL-positive cells in the ischemic myocardium of dogs. These effects of EPO were abolished by the treatment with wortmannin. In conclusion, EPO administered just before reperfusion reduced infarct size and the incidence of ventricular fibrillation via the PI3 kinase-dependent pathway in canine hearts. EPO administration can be a realistic strategy for the treatment of acute myocardial infarction.Keywords
This publication has 34 references indexed in Scilit:
- Phosphatidylinositol-3-Kinase Signaling Is Required for Erythropoietin-Mediated Acute Protection Against Myocardial Ischemia/Reperfusion InjuryCirculation, 2004
- Cardioprotective Effects of Erythropoietin in the Reperfused Ischemic HeartJournal of Biological Chemistry, 2004
- The decision to prematurely terminate a trial of R-HuEPO due to thrombotic eventsJournal of Pain and Symptom Management, 2004
- Erythropoietin in cardiovascular diseasesEuropean Heart Journal, 2004
- Reperfusion Arrhythmias: New Insights into the Role of the Na+/Ca2+ExchangerJournal of Molecular and Cellular Cardiology, 2001
- Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.Endocrine-Related Cancer, 2001
- Nuclear Mitogen-activated Protein Kinase Activation by Protein Kinase Cζ during Reoxygenation after Ischemic HypoxiaJournal of Biological Chemistry, 2000
- Myocardial reperfusion injury: Role of oxygen radicals and potential therapy with antioxidantsThe American Journal of Cardiology, 1994
- Factors that determine the occurrence of reperfusion arrhythmiasAmerican Heart Journal, 1988
- Correlates of reperfusion ventricular fibrillation in dogsThe American Journal of Cardiology, 1984